Recently, Emanuel Petriocoin and Lance Liotta of George Mason University’s (GMU) Center for Applied Proteomics & Molecular Medicine (CAPMM) discovered that activation of the protein ALK (anaplastic lymphoma kinase) is associated with inflammatory breast cancer, a particularly aggressive form of the disease: “Mason Research Gives Hope to Women With Deadliest Breast Cancer”.
Although this study was not funded by The Side-Out Foundation, Side-Out is incredibly proud to be associated with CAPMM through research in related clinical trials for breast cancer (see the Side-Out Protocol and I-SPY 2). The findings of the inflammatory breast cancer study may be put to use in the second phase of the Side-Out Protocol.
Comments: 1 Leave a comment
This is indeed an exciting finding. Hopefully more study will validate the results and open ALK targeting as a new treatment option for appropriate IBC patients.
It would be wonderful if this work would lead to an IBC specific arm of the 2nd phase of the Side-Out Protocol.